news

Our latest
Press Releases & Updates

Latest press releases

RetinAI attends ARVO 2022

RetinAI will attend the ARVO 2022 Annual Meeting in Denver, Colorado, from May 1st to 4th at the Colorado Convention Center. RetinAI will showcase its innovative data management and AI analysis solutions to optimize and simplify clinical development workflows for stakeholders in pharma, research and clinics. ARVO attendees who visit RetinAI at Booth #3008 will benefit from learning and seeing live demos on RetinAI Discovery for clinical studies, Discovery UNITY and RetinAI's Disease Evaluation Apps.
read more

RetinAI highlights Geographic Atrophy research with models available for analysis to enable the right decision sooner during clinical studies

RetinAI is pleased to share research findings from three published papers in Geographic Atrophy (GA). In collaboration with the Department of Ophthalmology at the University of Lausanne, Jules-Gonin Hospital, researchers at RetinAI developed a model for predicting atrophy risk in patients with non-exudative age-related macular degeneration (AMD).
read more

RetinAI announces a collaboration with Isarna Therapeutics

RetinAI Medical AG announced a collaboration with Isarna Therapeutics under which RetinAI’s IT solutions and artificial intelligence tools, including RetinAI Discovery®, shall be employed to support The BETTER Study, an international clinical trial evaluating the efficacy of ISTH0036 for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).
read more

RetinAI collaboration with Heidelberg Engineering gives customers access to RetinAI’s analysis models in OCT

Bern, Switzerland and Heidelberg, Germany – RetinAI Medical AG and Heidelberg Engineering have announced a collaboration which will enable Heidelberg Engineering’s customers to utilize RetinAI’s portfolio of artificial intelligence analysis tools in combination with high-quality OCT images. Thanks to cloud exchange and application marketplace technologies, SPECTRALIS® users will have the option of sending OCT volume scans for analysis using RetinAI’s tools in a convenient and secure manner.
read more

Latest updates

RetinAI in RTS- Swiss television

The last week of August we received the Swiss Television (SRF - Schweizer Radio und Fernsehen) at our offices in Bern.We talked for a few minutes about what we do and how artificial intelligence is going to change ophthalmology and healthcare in the near future!
‍
Watch it here

Arvo 2019 - Vancouver [MAY’19]

RetinAI had a great conference at this year at ARVO 2019, with more than 15’000 attendees from all over the world!Congratulations to the team for these amazing 5 days of work and for the success on the official release of our two main products: OmniViewer and RetinAI Discovery.

Democratising Access to Health Care - INVESTIERE [APRIL’19]

"Automation does not replace jobs, it replaces tasks" - Learn how RetinAI applies machine learning to medical imaging, not to replace eye doctors, but to make their work less tedious. Via Investiere Venture Capital - Read more

RetinAI in FORBES FR [DECEMBER’18]

RetinAI is honoured to be in December's edition of Forbes France! Artificial Intelligence is changing the world of ophthalmology by democratising access to high-quality eye-care for everyone. Discover a bit more about the future of healthcare in 2019, starting with your eyes! [FR]

‍

Contact us for more informations! We are happy to hear from you!

Contact Us

Ikerian AG (HQ)
‍Freiburgstrasse 3
3010 Bern
Switzerland
‍

RetinAI US Inc. (US)
6 Liberty Square
#2498 Boston, MA 02109
United States

Certifications
SolutionS For
Life Sciences & Pharma
Clinics & Hospitals
Device Manufacturers
Products
DISCOVERY
- UNITY
- For Clinical Studies
- For Clinics
REAL WORLD EVIDENCE
APPS FOR CLINICS
PRECISION MEDICINE
Contact
info@retinai.com
Media kit
Careers
Product User Manual

Imprint/Legal Notice  |  Data Processing Agreement  |  Privacy Notice  |  Created by Ikerian AG. All rights reserved 2016-2023 ©